key: cord-0819354-yhe5nla4
authors: Lieveld, Arthur W.E.; Azijli, Kaoutar; Teunissen, Bernd P.; van Haaften, Rutger M.; Kootte, Ruud S.; van den Berk, Inge A.H.; van der Horst, Sabine F.B.; de Gans, Carlijn; van de Ven, Peter M.; Nanayakkara, Prabath W.B.
title: Chest CT in COVID-19 at the ED: Validation of the COVID-19 Reporting and Data System (CO-RADS) and CT severity score
date: 2020-11-30
journal: Chest
DOI: 10.1016/j.chest.2020.11.026
sha: c03450f284bd16a058cd93488d4d09abef4c5cd8
doc_id: 819354
cord_uid: yhe5nla4

Background Computed tomography (CT) is thought to play a key role in COVID-19 diagnostic work-up. The possibility to compare data across different settings depends on the systematic and reproducible manner the scans are analyzed and reported. The COVID-19 Reporting and Data System (CO-RADS) and the corresponding CT severity score (CTSS) introduced by the Radiological Society of the Netherlands (NVvR) attempt to do so. However, this system has not been externally validated. Research question We aimed to prospectively validate the CO-RADS as a COVID-19 diagnostic tool at the emergency department (ED), and evaluate if the CTSS is associated with prognosis. Study Design Methods We conducted a prospective, observational study in two tertiary centers in The Netherlands, between March 19 and May 28, 2020. We consecutively included 741 adult patients at the ED with suspected COVID-19, who received a chest CT and SARS-CoV-2 PCR (PCR). Diagnostic accuracy measures were calculated for CO-RADS using PCR as reference. Logistic regression was performed for CTSS in relation to hospital admission, ICU admission and 30-day mortality. Results 741 patients were included. We found an AUC of 0.91 (CI 0.89-0.94) for CO-RADS using PCR as reference. The optimal CO-RADS cut-off was 4, with a sensitivity of 89.4% (CI 84.7-93.0) and specificity of 87.2% (CI 83.9-89.9). We found a significant association between CTSS and hospital admission, ICU admission, and 30-day mortality; adjusted odds ratios per point increase in CTSS were 1.19 (CI 1.09-1.28), 1.23 (1.15-1.32), 1.14 (1.07-1.22), respectively. Intra-class correlation coefficients for CO-RADS and CTSS were 0.94 (0.91-0.96) and 0.82 (CI 0.70-0.90). Interpretation Our findings support the use of CO-RADS and CTSS in triage, diagnosis and management decisions for patients presenting with possible COVID-19 at the ED.

The COVID-19 pandemic continues to put tremendous stress on healthcare systems and societies worldwide. With second waves flaring up globally, 1,2 swift and accurate diagnosis is essential to profile patients and allocate scarce resources adequately. This is still hampered by limited sensitivity and availability of SARS-CoV-2 PCR (PCR). [3] [4] [5] More importantly PCR does not give any insight into pulmonary involvement, while pneumonia is the most common cause of severe morbidity and mortality in COVID-19. 6, 7 Chest imaging may play a key role in COVID-19 triage and diagnosis, as well as stratification of disease severity. [8] [9] [10] Conventional chest radiography (CXR) unfortunately has limited sensitivity for COVID-19 pneumonia. In retrospective studies sensitivity of chest CT for COVID-19 is excellent and it may even be greater than that of PCR. [10] [11] [12] CTs are helpful in the diagnostic process at the emergency department (ED) because the results are available almost immediately and alternative diagnoses may be identified. In addition, using a semiquantitative CT severity score (CTSS) is reported to correlate with disease severity, and might be used as a prognostic marker. [12] [13] [14] [15] [16] [17] Studies on using CT as an initial diagnostic modality are mostly retrospective in nature and from China, possibly reducing their generalizability to other regions. Although the CT characteristics of COVID-19 have been documented properly, there is no universal agreement on a systematic and reproducible way of evaluating and reporting CT abnormalities in J o u r n a l P r e -p r o o f (suspected) COVID-19 patients, which makes it difficult to compare data across different settings. 8, 9, [18] [19] [20] [21] The Radiological Society of the Netherlands (NVvR) recently introduced such a method, the COVID-19 Reporting and Data System (CO-RADS), which is largely based on the recommendations of the Radiological Society of North America (RSNA). 9, 20, 22 The CO-RADS is meant to be used for patients with moderate to severe symptoms of (suspected) COVID-19. It employs a scoring system from 0 to 5 to classify pulmonary involvement from very unlikely to very likely, respectively (e- Table 1 ). In 105 patients the NVvR found a very good performance for predicting COVID-19 (AUC of 0.91 (CI 0.85-0.97). 20 In addition, interobserver agreement was substantial. Although these results are encouraging, a prospective external validation of the CO-RADS or any other CT classification system for COVID-19 is lacking.

In this observational study we therefore set out to prospectively validate the CO-RADS in two tertiary hospitals in The Netherlands. Furthermore, in accordance with recent research recommendations from the WHO 23 , we analyzed whether the CTSS was associated with hospital admission, ICU admission and mortality.

This is a real-life, prospective, observational study. Patients were recruited consecutively from the EDs of the two university hospitals in Amsterdam, the Netherlands between March 19 and May 28, 2020. The study was approved by the Medical Ethics Review Committee of the Amsterdam University Medical Centers, location VUmc. An opt-out recruitment procedure was used to obtain consent for participation in the study. All patients 18 years and older who visited the ED with suspected COVID-19 according to the   WHO and Dutch Centre for Infectious Disease Control case definition (including either fever, malaise, respiratory symptoms, gastro-intestinal symptoms or loss of taste and smell) were potentially eligible. Patients were included if they received a PCR and chest CT with CO-RADS score. Exclusion criteria were: age under 18, unwillingness to give verbal consent or a CO-RADS 6 score ( recommendations, dictated that physicians could perform a CT in case of moderate to severe symptoms. 23, 24 In case of mild symptoms physicians could forego additional imaging.

Hospital admission criteria were: saturation <94%, and/or respiratory rate >20/min. ICU admission criteria were: deterioration despite conventional respiratory support, patients requiring mechanical ventilation, or multi-organ failure. Admission decisions were not made based on CT data. All admitted patients with (suspected) COVID-19 were discussed daily in a multidisciplinary team (MDT), consisting of consultants in infectious disease, respiratory disease and microbiology. The MDT decided on the final diagnosis, but was not blinded for the CT results.

The CTs were assessed by our local radiologists with varying degrees of experience. The radiologists had regular access to clinical information, but did not have access to the PCR results, as CT scanning and reporting were done early after ED admission, before PCR results were available. The likelihood of COVID-19 pneumonia was reported according to the CO-J o u r n a l P r e -p r o o f RADS classification system (e -Table 1 ). 20, 22 Details on how the CT's were made are available in the e-Appendix under e-Methods.

To quantify pulmonary involvement, every CT with a CO-RADS of 3 or higher was graded according to the CT severity score (CTSS). 25 This is a visual assessment of the percentage of disease involvement in each lobe (e- Table 2 ). The total CTSS is the sum of the individual lobar scores and can range from 0 (no involvement) to 25 (maximum involvement).

A naso-or oropharynx PCR was performed in all patients presenting to ED, according to WHO standards. In case of a negative or inconclusive test result and high clinical suspicion of COVID-19, a naso-or oropharynx PCR was repeated or sputum or bronchoalvealar lavage if available and possible as indicated by the MDT.

As the primary outcome, sensitivity, specificity, predictive values, likelihood ratios, area under the receiver operating characteristic curve (AUROC) and diagnostic accuracy were calculated for CO-RADS. For CTSS we calculated the same measures, and odds ratios (OR) for hospital admission, ICU admission and mortality.

Continuous variables were summarized by their mean and standard deviation (SD), or by medians and interquartile range (IQR). Differences between groups were tested using the independent-samples t-test, Mann Whitney U test, chi-square test or Fisher's exact test as appropriate. A two-sided significance level of 5% was used, and 95%-confidence intervals were reported for all analyses.

Discriminatory ability of CO-RADS and CTSS was determined by the AUROC. The optimal cut-off value was determined by the Youden's index. Diagnostic measures were subsequently calculated.

For CTSS we also employed a 'grey zone' approach. A grey zone represents a predictive test of poor accuracy, with a sensitivity and specificity <90%. Sensitivity and specificity were plotted as a function of the CTSS, to determine a grey zone for hospital admission, ICU admission and mortality.

Logistic regression analysis was performed to test whether the CTSS score was associated with hospital-, ICU admission and 30-day mortality. Associations were quantified by odds ratios (ORs). We corrected for the following potential confounders: age, sex, and comorbidities (COPD, asthma, cardiovascular disease, hypertension). [12] [13] [14] [15] [16] [17] Inter-observer agreement was quantified between two acute radiologists, with 3 and 6 years of experience, and the initial assessing radiologist via the intra-class correlation coefficient (ICC). They independently assessed the CT images of 63 patients.

CUSUM charts were used to assess the learning curve for using CO-RADS for diagnosis of COVID-19. Two separate CUSUM charts were made; one for patients with a negative PCR (non-COVID) and one for patients with a positive PCR (COVID). In addition, CUSUM charts were made for overall accuracy including all patients.

From March 19 until May 28 2020, 1229 patients with symptoms suspected of COVID-19 presented at the two EDs. 741 patients fulfilled the inclusion criteria, of which 235 had a positive PCR result (see e- Table 3 for details on the excluded patients). In 56 of the PCR positive patients, the initial PCR was negative, and a repeated PCR testing was needed to confirm COVID-19. Patients in the PCR positive group were on average more likely to J o u r n a l P r e -p r o o f require oxygen therapy, hospital or ICU admission, and had a higher mortality rate. PCRpositive patients were also more likely to have comorbidities such as cardiovascular disease, hypertension and COPD (Table 1) . Figure 2 shows the distribution of PCR results with the CO-RADS score. We found that CO-RADS ≥ 4 was the optimal cut-off for discriminating between a positive and negative PCR, Table 2 ). The ICC was 0.94 (CI 0.91-0.96). 25 Patients had a false negative CT scan (CO-RADS ≤3, but positive PCR). Patients with a CO-RADS ≤ 2 had a significantly shorter duration of symptoms than those with a CO-RADS >2 (e- Table 4 ). Eleven (44%) of them had a symptom duration of less than three days.

Eighteen patients (72%) were admitted, 7 (28%) patients received oxygen and only 2 (8%) patients needed ICU treatment. 65 Patients had a false positive CT scan (CO-RADS ≥ 4, but negative PCR), compared to PCR. 46 Of those patients were still classified as having COVID-19 by the MDT, the remaining diagnoses are summarized in e- Table 5 . The most common alternative diagnoses were bacterial pneumonia and decompensated heart failure (e- Table 6 ).

The CUSUM plots in center 1 showed no strong up or downward inflictions indicating a steady performance over time. For center 2 an upward infliction was seen after the 80 th COVID-negative patient was included (corresponding to 161 th consecutive patient included),

showing a temporary increase in the false-positive rate (e- Figure 5 ).

J o u r n a l P r e -p r o o f CT severity score (CTSS)

The CTSS was determined in 304 (patients, who had a CO-RADS ≥3. Stratified according to three disease severity groups; 1) discharge home from ED, 2) hospital admission, or 3) ICU admission, we found a significant difference in mean CTSS; 5.5 (SD 3.6), 9.4 (SD 4.9), and 14.8 (4.8) respectively.

Logistic regression showed a significant positive association between CTSS (per point increase) and hospital admission, ICU admission, and 30-day mortality ( Table 3) Grey zone analysis showed that a CTSS ≥10 was predictive of hospital admission with a specificity of ≥90%, while a score of ≤3 was ≥90% sensitive for ED discharge. A CTSS ≥15 was predictive of ICU admission with a specificity of ≥90%, while a score ≤9 excluded ICU admission with a sensitivity of ≥90%. A score of ≥17 was ≥90% specific for 30-day mortality, while a score ≤5 excluded 30-day mortality with a sensitivity of ≥90% (e- Figure 4a-c) . The intra-class correlation coefficient for the CTSS was 0.82 (CI 0.7-0.9).

Discussion To our knowledge this is the first prospective multi-center study evaluating the diagnostic accuracy of chest CT in COVID-19 patients and externally validating a systematic CT reporting scheme. We found CO-RADS discriminates excellently between a positive and negative PCR result with an AUC of 0.91 (CI 0.89-0.94). We also found CTSS at ED presentation is associated with hospital admission, ICU admission and 30-day mortality. The CUSUM analysis showed no significant learning curve. In combination with a high interobserver agreement this indicates the system is easy to learn and use, even for less experienced radiologists.

The high negative predictive values and low negative likelihood ratios associated with a CO-RADS ≤3, indicate that these scores can aid in excluding the presence of COVID-19. A score of ≤3 could also aid in patient management, particularly patient isolation measures.

Interestingly, we found that almost half of the false negative CTs were performed in patients with a short duration of symptoms (<3 days). Previous studies found that chest imaging might be negative in the earlier phases of the disease, because it hasn't involved the lung parenchyma yet. 11 It is therefore important to note that scanning too early in the disease course could falsely reassure clinicians.

Our results indicate that a CO-RADS score ≥4 has a high positive likelihood ratio and a corresponding good PPV in a high prevalence setting. As was argued before by Ai et al. and Prokop et al. 11, 20 , the suboptimal clinical sensitivity of the gold standard PCR could result in a reduced specifity (and lower PPV and PLR) as this generates more false positive CTs. 3, 5 This would mean that specificity of CO-RADS might actually be higher in reality.

In any case, a CO-RADS ≥4 seems to ascertain the diagnosis of COVID-19. A score of ≥4 can therefore be used to put a patient in isolation or self-quarantine.

When COVID-19 prevalence decreases however, and/or the prevalence of similar diseases increase the positive predictive value of a high CO-RADS will likely decrease. Interestingly a recent Chinese/American study suggests that CT can distinguish COVID-19 from other viral pneumonias with moderate to high accuracy. 26 Further research is needed however to assess if CO-RADS is useful in a setting with a lower COVID-19 prevalence and a different case-mix of other (viral) diseases that might produce similar abonormalities on CT.

Our results externally validate CO-RADS as a reliable and reproducible tool in reporting pulmonary findings in patients suspected of COVID-19 in a pandemic setting. As stated in the RSNA Consensus statement, standardized reporting can provide guidance to radiologists, accelerate reporting during high demand, reduce reporting variability, enable care pathways, and facilitate a basis for data sharing, quality improvement and research. 9 CO-RADS can help achieve all those aims. Using CO-RADS could be especially helpful when PCR is not available and CT is conducted at the ED upon patient arrival as was the case in many Dutch hospitals during the pandemic. The Dutch Federation of Medical Specialists (FMS) has incorporated CO-RADS in the national COVID-19 care pathway recommendation. 24 

Our results indicate that CTSS is positively associated with hospital and ICU admission, and also -albeit to a lesser extent -30-day mortality even after correcting for confounders. The positive association of CTSS and hospital/ICU admission is greater than that of mortality. We also observed a smaller grey zone for hospital/ICU admission than 30-day mortality. This difference is probably explained because the time-to-event, in hospital/ICU admission is J o u r n a l P r e -p r o o f shorter than in 30-day mortality. Moreover, there are more complications of COVID-19 (i.e. pulmonary embolism) that also affect mortality and thus aren't captured by the CTSS.

However, although there are grey zones in each of these categories in which uncertainty remains, the upper and lower values can provide clinicians with a helpful tool to make faster and more adequate triage and management decisions, and predict patient disease course.

Especially since previous studies have shown that pulmonary involvement can predate worsening of severe respiratory symptoms. 13, 14 The CTSS could be particularly helpful in patients that don't seem clinically ill (e.g. silent hypoxia), but based on the CTSS might deteriorate and thus benefit from admission and a higher level of monitoring.

CT use -Global Perspective Although these results are encouraging there is still debate about the place of CT in COVID-19 diagnostics. Dutch and Chinese guidelines include CT in their work-up of COVID-19, while American and British guidelines are more reserved. The recent Fleishner consensus statement concedes that the logistics surrounding the provision of CT services can be a daunting task in the face of this pandemic. 8 As second waves are flaring up this is of particular importance. CT is difficult to perform in unstable patients, and availability and costs can be an issue even in high income countries. Risk of transmission during transport neccesitates stringent desinfection protocols and lead to prolonged CT down time. We have seen significant health disparities in COVID-19 outcome along geographic, socio-economic, ethnic, cultural and racial lines. [28] [29] [30] [31] Portable imaging modalities like bedside lung ultrasound circumvent these issues, while showing better accuracy than chest X-ray and similar accuracy to CT. 10,32-43 This may be considered as a viable alternative especially in low resource settings where CT might not be readily available.

Limitations/bias: Our study has some limitations. First, we stress that this study was conducted in a high prevalence setting. Although CO-RADS was designed to be used in patients with moderate to severe symptoms in this pandemic, it is unclear how CO-RADS will function when the pandemic subsides, but it is reasonable to assume that the false positive rate will increase in such a situation. Conversely, negative predictive value is likely to increase when disease prevalence decreases. However, we argue that the need for quick and reliable triage is more pressing in a pandemic setting than in a situation where prevalence is low and medical resources aren't as overwhelmed.

Second, we assessed diagnostic accuracy of CO-RADS and CTSS in population presenting to ED that were deemed to have moderate to severe symptoms, which justified additional imaging of the chest. While this might reduce generalizibility to all patients in all settings, the diagnostic accuracy measures we report are reflective of daily practice in EDs all over the globe. After all, physicians will be more likely to perform additional tests and exclude alternative diagnoses in patients with more severe symptoms than when symptoms are milder and less threatening.

It is yet unsure if CO-RADS would be applicable in asymptomatic or mildly symptomatic patients outside the ED, but the question is if this would be desirable. We would argue against the use of CT in the general out-patient population, because the possible benefits (early diagnosis, fast triage), probably do not outweigh the possible harms (overuse of medical resources, health care costs, radiation, increase of false negatives due to less pulmonary involvement in this group). Third, we feel selection bias was minimal, the treating physicians were not aware of this study being undertaken, so they weren't influenced in whether their patient got a CT or not. The chance of non-random selection of patients is therefore low. In addition, we consecutively included a very large consecutive sample of COVID-19 patients.

Fourth, information bias was minimized as the PCR results were not known at the time the CT was done, and if they were the results were excluded from the analysis. Fifth, the CO-RADS and CTSS was assessed by radiologists with varying levels of experience. However CUSUM analysis did not show clear learning effects in the participating hospitals. Combined with a high agreement this would suggest that both CO-RADS and CTSS are easy to use and reproduce.

Interpretation CO-RADS is an easy to use tool to help radiologists and guide clinicians in diagnosis of COVID-19 in patients with moderate to severe symptoms presenting to the ED. Furthermore the CTSS seems to correlate with hospital admission, ICU admission and 30-day mortality, and therefore might be used in management decisions. We encourage the international use of the CO-RADS and CTSS for patients with suspicion of COVID-19 at ED presentation, to provide a basis for further reporting, communication and data sharing. We also suggest further studies to be conducted in other countries and care settings to increase the robustness of our findings. J o u r n a l P r e -p r o o f

Coronavirus Update (Live) -Worldometers

Johns Hopkins Coronavirus Resource Center

Interpreting Diagnostic Tests for SARS-CoV-2

The Promise and Peril of Antibody Testing for COVID-19

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet

Clinical Characteristics of Coronavirus Disease 2019 in China

The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society

Radiological Society of North America Expert Consensus Statement on Reporting Chest CT Findings Related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA

Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases

Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease

The Clinical and Chest CT Features Associated With Severe and Critical COVID-19 Pneumonia

CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19)

Frequency and Distribution of Chest Radiographic

COVID-19 Positive Patients. Radiology

Clinical and High-Resolution CT Features of the COVID-19

Comparison of the Initial and Follow-up Changes. Investigative Radiology

Association between Initial Chest CT or Clinical Features and Clinical Course in Patients with Coronavirus Disease

Coronavirus Disease 2019 (COVID-19) CT Findings: A Systematic Review and Meta-analysis

S1546144020302623

A Systematic Review of Imaging Findings in 919 Patients

CO-RADS -A categorical CT assessment scheme for patients with suspected COVID-19: definition and evaluation

CT imaging features of 4121 patients with COVID-19: A metaanalysis

Handreiking Standaardverslag CT-thorax COVID inclusief CO-RADS en CTscore

Use of chest imaging in COVID-19

Diagnostiek bij verdenking COVID-19 en opname-indicatie

Pulmonary Sequelae in Convalescent Patients after Severe Acute Respiratory Syndrome: Evaluation with Thin-Section CT

Performance of Radiologists in Differentiating COVID-19 from Non-COVID-19 Viral Pneumonia at Chest CT

The role of CT in patients suspected with COVID-19 infection | The Royal College of

Ethnic and racial disparities in COVID-19-related deaths: counting the trees, hiding the forest

Widening Social and Health Inequalities During the COVID-19 Pandemic

Access to lifesaving medical resources for African countries: COVID-19 testing and response, ethics, and politics. The Lancet

Accuracy of Lung Ultrasonography versus Chest Radiography for the Diagnosis of Adult Community-Acquired Pneumonia: Review of the Literature and Meta-Analysis

A Preliminary Study on the Ultrasonic Manifestations of Peripulmonary Lesions of Non-Critical Novel Coronavirus Pneumonia (COVID-19)

Findings of lung ultrasonography of novel corona virus pneumonia during the 2019-2020 epidemic

Point-of-care lung ultrasound in patients with COVID -19 -a narrative review

Point-of-care ultrasonography in patients admitted with respiratory symptoms: a single-blind, randomised controlled trial. The Lancet Respiratory Medicine

Lung ultrasound in diagnosing pneumonia in the emergency department: a systematic review and meta-analysis

Lung Ultrasound for the Emergency Diagnosis of Pneumonia, Acute Heart Failure, and Exacerbations of Chronic Obstructive Pulmonary Disease/Asthma in Adults: A Systematic Review and Meta-analysis. The Journal of Emergency Medicine

Radiology and Imaging

Comparative study of lung ultrasound and chest computed tomography scan in the assessment of severity of confirmed COVID-19 pneumonia

Lung ultrasound predicts clinical course and outcomes in COVID-19 patients

Lung ultrasonography for risk stratification in patients with COVID-19: a prospective observational cohort study

Diagnosing COVID-19 pneumonia in a pandemic setting: Lung Ultrasound versus CT (LUVCT) A multi-centre, prospective, observational study

Age, mean (SD)

Admission IC, n (%)

Co-morbidities, n (%)

Specificity % (95%CI)

CTSS: CT-severity score; ICU: intensive care unit *Adjusted for age, sex, co-morbidities (cardiovascular disease, COPD, asthma, high blood pressure) Abbreviation list Abbreviations: AUC: area under the curve; AUROC: area under the receiver operating characteristic curve; CO-RADS: COVID-19 Reporting and Data System; CI: confidence interval; Reporting and Data System; CIE: change in estimate; COPD: chronic obstructive pulmonary disease; CT: Computed tomography; CTSS: Computed tomography severity score; CUSUM: cumulative sum control chart; CXR: chest radiograph; ED: Emergency department; FMS: Dutch Federation of Medical Specialists; ICC: intra-class correlation coefficient

MDT: multidisciplinary team of experts; NLR: negative likelihood ratio; NPV; negative predictive value; NVvR; Radiological Society of the Netherlands; OR: odds ratio; PCR: polymerase chain reaction; PLR; positive likelihood ratio

SD: standard deviation; ROC: receiver operating characteristic; WHO: World Health Organization; VUmc: Vrije Universiteit medical center

PN had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis, including and especially any adverse effects.AL, KA, BT, RvH, RK, IvdB, PvdV, SvdH, CG and PN contributed substantially to the study design, data analysis and interpretation, and the writing of the manuscript. There are no conflicts of interest to disclose. This study was not sponsored or funded in any way.